FRYL (FRY like transcription coactivator) is a conserved member of the Furry protein family with critical roles in developmental and cellular processes. Primary Function: FRYL functions as a transcriptional coactivator involved in regulating actin cytoskeleton dynamics and maintaining polarized cell morphology 1. In neuronal development, it promotes proper dendritic patterning by limiting branching and preventing inappropriate homologous dendrite interactions. Mechanism: FRYL operates within the Notch signaling pathway as a coactivator alongside MAML2, controlling expression of soluble guanylyl cyclase in vascular tissue 2. It interacts with multiple protein partners including NHLRC2, EIF2AK2, and KLHL13 3. Disease Relevance: Heterozygous loss-of-function variants in FRYL cause developmental delay, intellectual disability, dysmorphic features, and congenital anomalies through haploinsufficiency mechanisms 1. FRYL has been implicated in therapy-related acute myeloid leukemia through MLL translocations 4 and identified in malignant transformation of Waldenström's macroglobulinemia to diffuse large B-cell lymphoma 5. Clinical Significance: FRYL establishes a novel Mendelian developmental disorder and represents a potential therapeutic target in cancer progression and infection resistance 6. Reduced FRYL expression correlates with hypertension-associated vascular dysfunction.